|Bid||44.24 x 1000|
|Ask||44.31 x 1000|
|Day's range||44.14 - 44.55|
|52-week range||26.19 - 44.56|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||36.93|
|Forward dividend & yield||N/A (N/A)|
|1y target est||41.43|
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.
Company Announcement COPENHAGEN, Denmark; November 23, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish tradin
The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.